Retatrutide 100mg | 10-Vial Kit | Triple GIP/GLP-1/Glucagon Agonist | Obesity & Metabolic Research

Description

What is Retatrutide??

Retatrutide (LY3437943, CAS 2381932-72-3) is a 39-amino acid triple-receptor agonist simultaneously activating the GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR) — the first clinically investigated triagonist incretin peptide. Developed by Eli Lilly, it incorporates a C18 fatty diacid moiety for albumin binding, yielding a half-life of approximately 6 days. Phase 2 data demonstrated up to ~24% body weight reduction — exceeding tirzepatide (dual GIP/GLP-1) — primarily attributed to the additive glucagon receptor arm driving hepatic fat oxidation, thermogenesis, and appetite suppression independent of insulin secretion. Retatrutide is the leading research tool for dissecting the individual and combined contributions of all three incretin-related receptor axes.